Moberg Pharma: Moberg Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024

Moberg Pharma AB (publ) reported earnings results for the second quarter and six months ended June 30, 2024. For the second quarter, the company reported sales was SEK 4.11 million. Net loss was SEK 4.05 million compared to SEK 3.85 million a year ago. Basic loss per share from continuing operations was SEK 0.13 compared to SEK 0.39 a year ago. Diluted loss per share from continuing operations was SEK 0.13 compared to SEK 0.39 a year ago. For the six months, sales was SEK 4.93 million. Net loss was SEK 10.54 million compared to SEK 8.88 million a year ago. Basic loss per share from continuing operations was SEK 0.36 compared to SEK 0.9 a year ago. Diluted loss per share from continuing operations was SEK 0.36 compared to SEK 0.9 a year ago.